Slide 1: First Half 2023 Results Conference Call and Webcast
First Half 2023 Results Conference Call and Webcast August 10, 2023 Nasdaq: ZYME | zymeworks.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral commentary include “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchan
Slide 3: Chris Astle, Ph.D. - Senior Vice President & Chief Financial Officer
Chris Astle, Ph.D. Senior Vice President & Chief Financial Officer Making a Meaningful Difference 3
Slide 4: First Half 2023 Financial Results
First Half 2023 Financial Results • Revenue in 1H23 primarily driven by $40.9 million, net of a In millions USD 1H22 1H23 credit issued to Jazz for amendments to our partnership agreement, for development support and drug supply Revenue $7.4 $42.6 revenue from Jazz • R&D Expense decrease primarily d
Slide 5: Zanidatamab: Financial Terms of Licensing Agreement with Jazz
Zs Zanidatamab: Financial Terms of Licensing Agreement with Jazz Licensing Agreement Terms1 Summary of 1H 2023 Financial Impacts Counterparty • Sale and purchase agreement Upfront Payments $375,000,000 received in 4Q22 of zanidatamab development program to Jazz included $15M Regulatory Milestones Up
Slide 6: Important Anticipated Milestones & Opportunities Throughout Product Pipeline
Important Anticipated Milestones & Opportunities Throughout Product Pipeline 2023 2024 • Phase 2 1L GEA Follow-Up • Submit 2 IND Applications (presented January 19 at ASCO GI) for ZW171 and ZW191 zanidatamab + chemotherapy • HERIZON-GEA-01 • Additional publications on preclinical development Anticip
Slide 7: Zanidatamab: Recent Data Continue to Support Broad Activity in HER2-expressing Cancers
Zanidatamab: Recent Data Continue to Support Broad Activity in HER2-expressing Cancers HERIZON-BTC-01 Phase 1b/2 data in 1L mBC Full Clinical Results (ASCO 2023) Updated Results Presented by BeiGene (ASCO 2023) • cORR of 41.3% [95% CI: 30.4, 52.8] • cORR of 90.9% [95% CI: 75.7, 98.1] • mDOR of 12.9
Slide 8: Zanidatamab: Data Continue to Support Broad Activity in HER2-expressing GEA
Zanidatamab: Data Continue to Support Broad Activity in HER2-expressing Gastroesophageal Adenocarcinoma (GEA) Phase 2 data in 1L GEA Phase 1b/2 data in 1L G/GJEC Updated Clinical Results (ASCO GI 2023) Preliminary Results Presented by BeiGene (ASCO 2022) • cORR of 79% [95% CI: 63, 90] • cORR of 75.8
Slide 9: Differentiated Development of Multi-Specific Antibody Therapeutics
Differentiated Development of Multi-Specific Antibody Therapeutics Versatile multi-specific antibody therapeutics designed for potency and precision, with a robust clinical pipeline Program Potential Indication Target(s) Preclinical Phase 1 Phase 2 Pivotal Collaboration Partners Zanidatamab BTC HER2
Slide 10: Differentiated Development of Antibody Drug Conjugates
Differentiated Development of Antibody Drug Conjugates Designing next-generation antibody drug conjugates (ADCs) on targets with evidence of clinical activity and addressing areas of unmet therapeutic potential Program Potential Target(s) Payload DAR (Range) Preclinical Phase 1 Phase 2 Pivotal Colla
Slide 11: Q&A
Q&A Kenneth Galbraith Chair and CEO Chris Astle, Ph.D. SVP and CFO Paul Moore, Ph.D. CSO Making a Meaningful Difference 11